Shanghai Henlius Biotech Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Shanghai Henlius Biotech is de winst gegroeid met een gemiddeld jaarlijks percentage van 37.4%, terwijl de Biotechs industrie de winst jaarlijks groeide met 31.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 57% per jaar. Het rendement op eigen vermogen van Shanghai Henlius Biotech is 26.9%, en het heeft een nettomarge van 12.3%.

Belangrijke informatie

37.4%

Groei van de winst

38.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie	11.0%
Inkomstengroei	57.0%
Rendement op eigen vermogen	26.9%
Nettomarge	12.3%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 22

Opbrengsten en kosten

Hoe Shanghai Henlius Biotech geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SEHK:2696 Opbrengsten, kosten en inkomsten (CNY Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	5,641	692	2,281	1,053
31 Mar 24	5,518	619	2,225	1,086
31 Dec 23	5,395	546	2,168	1,119
30 Sep 23	5,008	55	1,914	1,309
30 Jun 23	4,426	-203	2,011	1,408
31 Mar 23	3,820	-449	1,808	1,401
31 Dec 22	3,215	-695	1,604	1,395
30 Sep 22	2,659	-638	1,248	1,189
30 Jun 22	2,338	-842	1,025	1,107
31 Mar 22	2,010	-913	913	1,065
31 Dec 21	1,682	-984	801	1,024
30 Sep 21	1,397	-962	716	988
30 Jun 21	1,111	-939	632	953
31 Mar 21	849	-966	534	924
31 Dec 20	588	-994	436	894
30 Sep 20	386	-1,000	349	835
30 Jun 20	184	-1,007	262	776
31 Mar 20	145	-941	243	704
31 Dec 19	91	-875	221	608
30 Sep 19	58	-747	185	525
30 Jun 19	24	-619	150	441
31 Mar 19	8	-591	131	416
31 Dec 18	7	-494	109	365
31 Dec 17	34	-271	87	257

Kwaliteitswinsten: 2696 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: 2696 is in het verleden winstgevend geweest.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 2696 is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 37.4% per jaar laten groeien.

Versnelling van de groei: 2696 is het afgelopen jaar winstgevend geworden, waardoor de winstgroei moeilijk te vergelijken is met het 5-jarig gemiddelde.

Winst versus industrie: 2696 is het afgelopen jaar winstgevend geworden, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs -sector ( 4% ).

Rendement op eigen vermogen

Hoge ROE: Hoewel het rendement op eigen vermogen ( 26.85% ) van 2696 hoog is, is deze metriek vertekend vanwege hun hoge schuldenniveau.

Shanghai Henlius Biotech Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

Shanghai Henlius Biotech, Inc. to Report First Half, 2024 Results on Aug 26, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023

Recent updates

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Shanghai Henlius Biotech, Inc. Announces First Patient in Japan Dosed in an International Multicentre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) in Combination with Bevacizumab Injection and Chemotherapy for the First-Line Treatment of Metastatic Colorectal Cancer (mCRC)

Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

Shanghai Henlius Biotech, Inc. Receives Positive Opinion from the Committee Formedicinal Products for Human Use (Chmp)Of the European Medicines Agency (Ema)

Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of Pembrolizumab Biosimilar HLX17 (Recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection)

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

Shanghai Henlius Biotech, Inc. Announces Company Secretary Changes

Shanghai Henlius Biotech, Inc. to Report First Half, 2024 Results on Aug 26, 2024

Shanghai Henlius Biotech, Inc. Announces the First Patient Dose in A Phase 2 Clinical Trial of HLX53

Shanghai Henlius Biotech, Inc. Announces International Multicentre Phase 3 Clinical Trial for the First-Line Treatment of Metastatic Colorectal Cancer in Japan

Shanghai Henlius Biotech, Inc. Announces Chief Financial Officer Changes

Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) agreed to acquire 78.3% stake in Shanghai Henlius Biotech, Inc. (SEHK:2696) from a group of shareholders for CNY 4.3 billion.

Investor sentiment improves as stock rises 19%

Less than half of directors are independent

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications

Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration (FDA)

Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration

New major risk - Financial position

Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Shanghai Henlius Biotech, Inc. Receives Approval from United States Food and Drug Administration for Application for Phase 1 Clinical Trial of HLX42 for Injection (Antibody-Drug Conjugate Targeting EGFR with Novel DNA Topoisomerase I Inhibitor)

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13

New minor risk - Financial position

Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023

Shanghai Henlius Biotech, Inc. Announces Shenzhen Nansiuzhuiang in Combination with Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Shanghai Henlius Biotech, Inc. Announces NMPA Approvals of Two ADC Candidates for IND

Shanghai Henlius Biotech, Inc. Announces the First Patient in Europe Has Been Dosed in the International Multi-Centre Phase 3 Clinical Trial

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication of Hansizhuang (Serplulimab Injection) an Innovative Anti-PD-1 Monoclonal Antibody

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.47 loss in 1H 2022)

Shanghai Henlius Biotech, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Consensus EPS estimates fall by 31%

Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Phase 2 Clinical Trial of HLX26

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

Shanghai Henlius Biotech, Inc. Announces Application for Phase 2 Clinical Trial of Hlx26

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Consensus revenue estimates increase by 13%

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces United States Food and Drug Administration Accepts the Biologic License Application for HLX02

Shanghai Henlius Biotech, Inc. Announces the First Patient in USA Has Been Dosed in Aninternational Multicentre Phase 3 Clinical Study Ofrecombinant Anti-Vegf Humanised Monoclonalantibody Ophthalmic Injection Hlx04-Ofor the Treatment of Wet Age-Related Maculardegeneration (Wamd)

Shanghai Henlius Biotech, Inc. Announces the Phase 1b/2 Clinical Trial of Hlx07

Shanghai Henlius Biotech, Inc. Announces Dosage of First Subject in Phase 1 Clinical Study of HLX15 (Recombinant Anti-CD38 Humanmonoclonal Antibody Injection) in Healthy Chinese Male Subjects